MCM
ANIK icon

Matarin Capital Management’s Anika Therapeutics ANIK Stock Holding History

Matarin Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,615
Closed -$411K – 188
2020
Q3 		$411K Sell
11,615
-8,909
-43% -$322K 0.09% 178
2020
Q2 		$774K Sell
20,524
-12,075
-37% -$398K 0.15% 159
2020
Q1 		$942K Sell
32,599
-98,866
-75% -$4M 0.15% 161
2019
Q4 		$6.82M Sell
131,465
-58,515
-31% -$3.4M 0.65% 58
2019
Q3 		$10.4M Buy
189,980
+159,891
+531% +$8.21M 0.79% 48
2019
Q2 		$1.22M Buy
+30,089
New +$1.1M 0.09% 194

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Matarin Capital Management's ANIK Position: Q4 2020 in Review

Matarin Capital Management sold out of Anika Therapeutics (ANIK) in Q4 2020, closing a stake of 11,615 shares — an estimated $411K sold.

Matarin Capital Management first reported a position in ANIK in Q2 2019 and held it in 6 quarters. The position peaked at $10.4M in Q3 2019. 164 funds tracked by Wall St. Rank hold ANIK as of Q4 2020.

  • Matarin Capital Management reported no remaining Anika Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Matarin Capital Management sold 11,615 Anika Therapeutics shares in Q4 2020, an estimated $411K.
  • Matarin Capital Management first reported a position in Anika Therapeutics in Q2 2019 and held it in 6 quarters.
  • Matarin Capital Management's Anika Therapeutics position peaked at $10.4M in Q3 2019.
  • 164 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.